B
Benjamin F. Cravatt
Researcher at Scripps Research Institute
Publications - 698
Citations - 69790
Benjamin F. Cravatt is an academic researcher from Scripps Research Institute. The author has contributed to research in topics: Fatty acid amide hydrolase & Anandamide. The author has an hindex of 131, co-authored 666 publications receiving 61932 citations. Previous affiliations of Benjamin F. Cravatt include Pfizer & Indiana University.
Papers
More filters
Journal ArticleDOI
NNMT promotes epigenetic remodeling in cancer by creating a metabolic methylation sink
TL;DR: This paper showed that NNMT impairs the methylation potential of cancer cells by consuming methyl units from S-adenosyl methionine to create the stable metabolic product 1-methylnicotinamide.
Journal ArticleDOI
The Metabolic Serine Hydrolases and Their Functions in Mammalian Physiology and Disease
TL;DR: A comprehensive summary that captures the state of knowledge about mammalian metabolic SHs in their entirety, including those enzymes that remain mostly or completely uncharacterized.
Journal ArticleDOI
The endocannabinoid system drives neural progenitor proliferation
Tania Aguado,Krisztina Monory,Javier Palazuelos,Nephi Stella,Benjamin F. Cravatt,Beat Lutz,Giovanni Marsicano,Zaal Kokaia,Manuel Guzmán,Ismael Galve-Roperh +9 more
TL;DR: It is demonstrated that progenitor cells express a functional endocannabinoid system that actively regulates cell proliferation both in vitro and in vivo, and thus open novel therapeutic avenues for manipulation of NP cell fate in the adult brain.
Journal ArticleDOI
Fatty acid amide hydrolase: an emerging therapeutic target in the endocannabinoid system
TL;DR: Pharmacological strategies to augment endogenous cannabinoid ('endocannabinoid') activity with FAAH inhibitors, which might exhibit superior selectivity in their elicited behavioral effects compared with direct CB1 agonists are proposed.
Journal ArticleDOI
Ligand and Target Discovery by Fragment-Based Screening in Human Cells
Christopher G. Parker,Andrea Galmozzi,Yujia Wang,Bruno E. Correia,Kenji Sasaki,Christopher M. Joslyn,Arthur S. Kim,Cullen L. Cavallaro,R. Michael Lawrence,Stephen R. Johnson,Iñigo Narvaiza,Enrique Saez,Benjamin F. Cravatt +12 more
TL;DR: A platform that marries fragment-based ligand discovery with quantitative chemical proteomics to map thousands of reversible small molecule-protein interactions directly in human cells and facilitates the coordinated discovery of bioactive small molecules and their molecular targets is described.